This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Changes in tryptophan metabolite levels in the pathogenesis of inflammatory bowel diseases
1 Pirogov Russian National Research Medical University, Moscow, Russia
2 Kazan State Medical University, Kazan, Russia
3 Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russia
4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Correspondence should be addressed: Vladimir A. Sorokin
Ostrovityanova, 1, Moscow, 117997, Russia; ur.liam@a_v_nikoros
Funding: the article is based on the results of implementation of Grant Agreement No. 075-15-2022-310 of April 20, 2022, which provides for federal budget subsidies as state support for the establishment and development of world-class scientific centers conducting research and development in priority areas of scientific and technological advancement.
Author contribution: Sorokin VA — data collection and analysis, literature analysis, manuscript preparation; Apollonova SA — physico-chemical and laboratory analyses, data analysis; Abdulkhakov SR — study planning, data analysis; Shakirova GF — data collection and analysis, literature analysis; Odintsova AH — data collection, patient examination and supervision; Abdulkhakov RA — study planning, data interpretation; Rumyantsev SA — study planning, general guidance; Shestopalov AV — study planning, data analysis, manuscript editing.
Compliance with ethical standards: the study was approved by the Ethics Committee of the Pirogov Russian National Research Medical University (Minutes No. 186 of June 26, 2019). All patients signed a voluntary informed consent to participate in the study.
- Wang S, van Schooten FJ, Jin H, Jonkers D, Godschalk R. The involvement of intestinal tryptophan metabolism in inflammatory bowel disease identified by a meta-analysis of the transcriptome and a systematic review of the metabolome. Nutrients. 2023; 15 (13): 2886. DOI:10.3390/nu15132886.
- Belousova EA, Shelygin YuA, Achkasov SI, Hatkov IE, Bakulin IG, Skalinskaya MI, i dr. Kliniko-demograficheskie harakteristiki i lechebnye podhody u pacientov s vospalitel'nymi zabolevaniyami kishechnika (bolezn' Krona, yazvennyj kolit) v Rossijskoj Federacii. Pervye rezul'taty analiza Nacional'nogo registra. Koloproktologiya. 2023; 22 (1): 65–82. DOI:10.33878/2073-7556-2023-22-165-82. Russian.
- GBD 2017 Inflammatory Bowel Disease Collaborators. Global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020; 5 (1): 17–30. DOI: 10.1016/S2468-1253(19)30333-4.
- Laurans L, Taleb S. Impact du catabolisme intestinal du Tryptophane dans les maladies inflammatoires [Impact of intestinal catabolism of tryptophan in inflammatory diseases]. Cah Nutr Diet. 2024; 59 (3): 184–93. French. DOI: 10.1016/j.cnd.2024.03.001.
- Taubenheim J, Kadibalban AS, Zimmermann J, Taubenheim C, Tran F, Schreiber S, et al. Metabolic modeling reveals a multi-level deregulation of host-microbiome metabolic networks in IBD. Nat Commun. 2025; 15 (1): 5120. DOI: 10.1038/s41467-025-60233-2.
- Larussa T, Imeneo M, Luzza F. The kynurenine pathway in inflammatory bowel disease: a critical review. J Inflamm Res. 2020; 13: 387–96. DOI: 10.2147/JIR.S250550.
- Hou JJ, Ma AH, Qin YH. Activation of the aryl hydrocarbon receptor in inflammatory bowel disease: insights from gut microbiota. Front Cell Infect Microbiol. 2023; 13: 1279172. DOI: 10.3389/fcimb.2023.1279172.
- Gecina ML, Chernevskaya EA, Beloborodova NV. Rol' obshchih dlya cheloveka i mikrobioty metabolitov triptofana pri tyazhelyh zabolevaniyah i kriticheskih sostoyaniyah (obzor). Klinicheskaya praktika. 2020; 11 (1): 92–102. DOI: 10.17816/clinpract21217. Russian.
- Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020; 17 (4): 223–7. DOI: 10.1038/s41575-019-0258-z.
- Scott SA, Fu J, Chang PV. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proc Natl Acad Sci USA. 2020; 117 (32): 19376–87. DOI: 10.1073/pnas.2000047117.
- Vich Vila A, Zhang J, Liu M, Faber KN, Weersma RK. Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases. Gut. 2024; 73 (11): 1909–20. DOI: 10.1136/gutjnl-2023-329969-3.
- Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 2018; 23 (6): 716–24. DOI: 10.1016/j.chom.2018.05.003.
- Bernardi F, D'Amico F, Bencardino S, Faggiani I, Fanizza J, Zilli A, et al. Gut microbiota metabolites: unveiling their role in inflammatory bowel diseases and fibrosis. Pharmaceuticals. 2024; 17 (3): 347. DOI: 10.3390/ph17030347.
- Krause FF, Mangold KI, Ruppert AL, Leister H, Hellhund-Zingel A, Lopez Krol A, et al. Clostridium sporogenes-derived metabolites protect mice against colonic inflammation. Gut Microbes. 2024; 16 (1): 2412669. DOI: 10.1080/19490976.2024.2412669.
- Yu K, Li Q, Sun X, Peng X, Tang Q, Chu H, et al. Bacterial indole-3-lactic acid affects epithelium–macrophage crosstalk to regulate intestinal homeostasis. Proc Natl Acad Sci USA. 2023; 120 (45): e2309032120. DOI: 10.1073/pnas.2309032120.
- Desmons A, Humbert L, Eguether T, Krasniqi P, Rainteau D, Mahdi T, et al. High-performance liquid chromatography–tandem mass spectrometry quantification of tryptophan metabolites in human serum and stool — Application to clinical cohorts in Inflammatory Bowel Diseases. J Chromatogr A. 2022; 1685: 463602. DOI: 10.1016/j.chroma.2022.463602.
- Ala M. Tryptophan metabolites modulate inflammatory bowel disease and colorectal cancer by affecting immune system. Int Rev Immunol. 2022; 41 (3): 326–45. DOI: 10.1080/08830185.2021.1954638.
- Xia Y, Liu C, Li R, Zheng M, Feng B, Gao J, et al. Lactobacillus-derived indole-3-lactic acid ameliorates colitis in cesarean-born offspring via activation of aryl hydrocarbon receptor. iScience. 2023; 26 (11): 108279. DOI: 10.1016/j.isci.2023.108279.
- Gasaly N, de Vos P, Hermoso MA. Impact of bacterial metabolites on gut barrier function and host immunity: a focus on bacterial metabolism and its relevance for intestinal inflammation. Front Immunol. 2021; 12: 658354. DOI: 10.3389/fimmu.2021.658354.
- Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun. 2018; 9: 3294. DOI: 10.1038/s41467-018-05470-4.
- Dodd D, Spitzer MH, Van Treuren W, Merrill BD, Hryckowian AJ, Higginbottom SK, et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature. 2017; 551 (7682): 648–52. DOI: 10.1038/nature24661.
- Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut. 2021; 70 (6): 1174–82. DOI: 10.1136/gutjnl-2020-323071.
- Hu Y, Chen Z, Xu C, Kan S, Chen D. Disturbances of the gut microbiota and microbiota-derived metabolites in inflammatory bowel disease. Nutrients. 2022; 14 (23): 5140. DOI: 10.3390/nu14235140.
- Fu Y, Lyu J, Wang S. The role of intestinal microbes on intestinal barrier function and host immunity from a metabolite perspective. Front Immunol. 2023; 14: 1277102. DOI: 10.3389/fimmu.2023.1277102.
- Wang M, Guo J, Hart AL, Li JV. Indole-3-aldehyde reduces inflammatory responses and restores intestinal epithelial barrier function partially via aryl hydrocarbon receptor (AhR) in experimental colitis models. J Inflamm Res. 2023; 16: 5845–64. DOI: 10.2147/JIR.S432747.